Idorsia (OTCMKTS:IDRSF) Stock Falls 5.4% – Here’s Why

Idorsia Ltd (OTCMKTS:IDRSF) fell 5.4% during trading on Thursday. The stock traded as low as $5.30 and last traded at $5.30. Approximately 200 shares were traded during trading, a decline of 98% from the average daily volume of 9,700 shares. The stock had previously closed at $5.60.

Analyst Ratings Changes

A number of equities analysts have recently weighed in on IDRSF shares. Deutsche Bank Aktiengesellschaft reaffirmed a “hold” rating on shares of Idorsia in a research report on Monday, August 3rd. HC Wainwright reissued a “buy” rating on shares of Idorsia in a research report on Monday, September 14th. One analyst has rated the stock with a Buy rating and one has given a Hold rating to the stock. According to data from MarketBeat, Idorsia currently has an average rating of “Moderate Buy”.

Idorsia Price Performance

The stock’s fifty day moving average is $7.00 and its two-hundred day moving average is $5.96.

Idorsia Company Profile

Idorsia Ltd. is a biopharmaceutical company headquartered in Allschwil, Switzerland. The company was established in 2017 following the acquisition of Actelion by Johnson & Johnson, with Idorsia retaining Actelion’s research and development operations and a portfolio of pharmaceutical assets.

Idorsia discovers and develops medicines for conditions with significant unmet medical needs, focusing primarily on cardiovascular disease, central nervous system disorders, immunology and rare diseases.